Q-omics provides the consensus-scored KIF15 profile across patient tissues and cancer cell-line models. KIF15 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KIF15 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, KIF15 RNA expression shows 28,270 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, BLCA, and LSCC as cancer lineages where KIF15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF15 survival associations across molecular data types. KIF15 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF15 RNA expression–survival associations across cancer types. High KIF15 expression shows unfavorable associations in KIRP, ACC, MESO, LIHC and KICH, but favorable associations in UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for KIF15 RNA expression.
This table summarizes KIF15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KIF15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF15 shows higher tumor expression in BLCA, LUAD, KIRP, STAD, KIRC and LIHC. The BLCA box plot shows higher KIF15 RNA expression in tumor versus normal tissue (log2 FC = +2.562, t-test p < 0.001).
This table shows molecular features associated with KIF15 in patient tissues and cancer cell lines. In patient samples, KIF15 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
